JPS61501848A - マイトマイシンの溶液 - Google Patents

マイトマイシンの溶液

Info

Publication number: JPS61501848A
Authority: JP; Japan
Prior art keywords: solution; mitomycin; days; activity; day
Prior art date: 1984-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP60501600A

Other languages

English (en)

Japanese (ja)

Inventor

ホフマン，ノーマン　イー

Original Assignee

バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-04-10

Filing date

1985-04-05

Publication date

1986-08-28

1985-04-05 Application filed by バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテッド filed Critical バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテッド

1986-08-28 Publication of JPS61501848A publication Critical patent/JPS61501848A/ja

Status Pending legal-status Critical Current

Links

NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 title claims description 29
229960004857 mitomycin Drugs 0.000 title claims description 28
229930192392 Mitomycin Natural products 0.000 title claims description 27
239000000243 solution Substances 0.000 claims description 28
239000000872 buffer Substances 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
238000007710 freezing Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
239000002246 antineoplastic agent Substances 0.000 description 4
238000011340 continuous therapy Methods 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000008355 dextrose injection Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000001540 sodium lactate Substances 0.000 description 2
229940005581 sodium lactate Drugs 0.000 description 2
235000011088 sodium lactate Nutrition 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000981595 Zoysia japonica Species 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
YVBGRQLITPHVOP-UHFFFAOYSA-L disodium;[hydroxy-[hydroxy(oxido)phosphoryl]oxyphosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)(=O)OP(O)([O-])=O YVBGRQLITPHVOP-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000011282 treatment Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP60501600A 1984-04-10 1985-04-05 マイトマイシンの溶液 Pending JPS61501848A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US59864584A	1984-04-10	1984-04-10
US598645		1984-04-10

Publications (1)

Publication Number	Publication Date
JPS61501848A true JPS61501848A (ja)	1986-08-28

Family

ID=24396387

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP60501600A Pending JPS61501848A (ja)	1984-04-10	1985-04-05	マイトマイシンの溶液

Country Status (3)

Country	Link
EP (1)	EP0179092A4 (de)
JP (1)	JPS61501848A (de)
WO (1)	WO1985004552A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5216011A (en) *	1989-09-01	1993-06-01	Bristol-Myers Squibb Co.	Stable solutions of mitomycin c
DE19957371A1 (de) *	1999-11-29	2001-06-13	Medac Klinische Spezialpraep	Mitomycin C-Lösung
ES2197817B2 (es) *	2002-06-10	2004-12-16	Laboratorios Casen-Fleet, S.A.	Procedimiento para la obtencion de una solucion hipertonica tamponada y solucion obtenida.
EP2079306A4 (de) *	2006-10-03	2009-12-30	Accentia Biopharmaceuticals In	Nicht schleimhautreizende amphotericin-b-formulierungen und verfahren zur behandlung nicht invasiver pilzinduzierter mucositis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3660578A (en) *	1957-04-06	1972-05-02	Kyowa Hakko Kogyo Kk	Mitomycin c
US3042582A (en) *	1958-12-11	1962-07-03	Bristol Myers Co	Mitomycin recovery from fermentation broth
US3152954A (en) *	1962-02-06	1964-10-13	American Cyanamid Co	Process of preparing mitomycin c
NL129868C (de) *	1963-06-07
JPS5240B2 (de) *	1973-12-17	1977-01-05
US4062964A (en) *	1975-12-03	1977-12-13	Ciba-Geigy Corporation	Antifertility-combinations
US4260619A (en) *	1980-02-19	1981-04-07	Ciba-Geigy Corporation	2-Aminoalkyl-5-pyridinols

1985
- 1985-04-05 EP EP19850901884 patent/EP0179092A4/de not_active Withdrawn
- 1985-04-05 WO PCT/US1985/000575 patent/WO1985004552A1/en not_active Ceased
- 1985-04-05 JP JP60501600A patent/JPS61501848A/ja active Pending

Also Published As

Publication number	Publication date
EP0179092A1 (de)	1986-04-30
WO1985004552A1 (en)	1985-10-24
EP0179092A4 (de)	1987-08-05

Similar Documents

Publication	Publication Date	Title
ES2256913T3 (es)	2006-07-16	Antagonistas de arginina para la inhibicion de la hipotension sistemica asociada a la produccion de oxido nitrico o al factor de relajacion derivado endotelial.
Whipple et al.	1944	Hemoglobin, plasma protein and cell protein—their interchange and construction in emergencies
ES2223549T3 (es)	2005-03-01	Formulacion que contiene moxifloxacino y sal comun.
Peden et al.	1972	Total parenteral nutrition in premature infants
TWI290045B (en)	2007-11-21	Lactate containing pharmaceutical composition and uses thereof
HU202761B (en)	1991-04-29	Process for producing stabilized erythropoietin compositions
BR112014009785B1 (pt)	2020-06-30	método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef)
US20060154891A1 (en)	2006-07-13	Ready-to-use gemcitabine solutions and gemcitabin concentrates
US5049396A (en)	1991-09-17	Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment
Madan et al.	1976	Total parenteral nutrition
Smith et al.	2004	Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device
US20050282776A1 (en)	2005-12-22	Injectable pharmaceutical compositions comprising sodium diclofenac and beta-cyclodextrin
US4185093A (en)	1980-01-22	Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals
JPH01501389A (ja)	1989-05-18	ポリペプチド製剤
Makarewicz et al.	1986	Prevention of superficial phlebitis during peripheral parenteral nutrition
Fox et al.	1978	Cerium sulphadiazine as a topical agent for burn wound infections: a comparison with silver sulphadiazine and zinc sulphadiazine
US4315942A (en)	1982-02-16	Intravenously administrable iron supplement
JPH03135918A (ja)	1991-06-10	免疫賦活剤
VAN ITALLIE et al.	1952	Clinical use of fat injected intravenously
JPS6048925A (ja)	1985-03-16	安定なｓ−アデノシル−ｌ−メチオニン塩を含有する注射可能な治療用組成物
WO1985004552A1 (en)	1985-10-24	Solutions of mitomycin
JPH06509362A (ja)	1994-10-20	アルファ−ケトルグルタル酸塩の用法
US7879814B2 (en)	2011-02-01	Methods and therapeutic compositions in the treatment of advanced cancer
JPH06135852A (ja)	1994-05-17	ウリナスタチン注射液
WO1984001506A1 (en)	1984-04-26	Pharmaceutical preparations for use in antitumour therapy